We are deeply saddened to report that a patient recently passed away while participating in Ambio's Detoxification Program. With our deepest respect for the privacy of our patient and their family, we will not discuss details of this incident publicly.

Nonetheless, we feel it is important, during a period of increasing interest in the promise offered by ibogaine treatment, to reiterate that there are ongoing risks associated with ibogaine as a detoxification treatment. Recently, these risks have been heightened and underscored by the increasing number of dangerous, unknown, and ever-changing adulterants in the global supply of street fentanyl.

The history of ibogaine includes serious adverse events, including fatalities. Forensic studies have identified a set of identifiable conditions that substantially increase the risk of taking ibogaine, such as pre-existing heart conditions and the recent consumption of certain types of drugs and medications.

Over the past several decades, there has been a concerted, communal effort to make ibogaine treatment safer and more available. In the process, the rate of adverse events has fallen substantially.

‍

‍

The patient journey at Ambio begins with careful screening and detailed preparation, which includes a complete medical history, lab tests, EKGs, and assessment of intention. Once patients arrive, screening and medical preparation continues, led by our staff of over 100 professionals in our clinics, with equipment for advanced life support. This effort takes time, patience, investment, and a high degree of professional medical competence.

Since we opened in 2021, we have continued to develop additional safety measures and have shared our insights with our industry peers, who have adopted our innovations into their clinics. We have gained a considerable understanding of the cardiac concerns surrounding ibogaine. However, in our Detoxification Program, the increasing complexity of powerful synthetic opioids and numerous other additives that appear in street drugs introduce a complex and opaque set of variables that can be difficult to mitigate. Ibogaine has been presented as a potential solution to the opioid crisis, however there are complex systemic barriers to resolving these issues.

In light of the evolving nature of the street drug supply, we will be implementing changes to our Detoxification Program. These changes include enhanced screening protocols, longer program durations for detox patients, and a minimum 21-day stay for anyone consuming fentanyl prior to treatment. These changes will, unfortunately, will make treatment less financially accessible for some candidates. However, it is our responsibility to react appropriately to this changing external environment for the safety of our Detoxification Program patients.

With increased demand for ibogaine treatment, alongside movements to federally reclassify and medicalize ibogaine in North America, the risks of ibogaine treatment in vulnerable populations is a topic that is currently not discussed enough. We believe that increased dialogue about risk reduction and informed consent will lead to growth that is ethical, responsible, and safer for all.

The responsibility of providing care in this complex, evolving field demands transparency, rigor, and integrity. The increased complexity in the global drug supply and treatment of patients suffering from addiction has further underlined the importance of our commitment to advancing safety standards for all who wish to pursue ibogaine treatment.